Switch theme
Sign up to access all valuation multiples
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (“FDA”).
2005
3
Last FY Revenue $0.1M
Last FY EBITDA -$9.1M
$94.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, NeOnc Technologies achieved revenue of $0.1M and an EBITDA of -$9.1M.
NeOnc Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NeOnc Technologies valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$9.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -10958% | XXX | XXX | XXX |
| EBIT | XXX | -$7.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -8556% | XXX | XXX | XXX |
| Net Profit | XXX | -$11.9M | XXX | XXX | XXX |
| Net Margin | XXX | -14335% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, NeOnc Technologies's stock price is $5.
NeOnc Technologies has current market cap of $94.6M, and EV of $94.5M.
See NeOnc Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94.5M | $94.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, NeOnc Technologies has market cap of $94.6M and EV of $94.5M.
NeOnc Technologies's trades at 1138.8x EV/Revenue multiple, and -10.4x EV/EBITDA.
Equity research analysts estimate NeOnc Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeOnc Technologies's P/E ratio is not available.
See valuation multiples for NeOnc Technologies and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $94.6M | XXX | $94.6M | XXX | XXX | XXX |
| EV (current) | $94.5M | XXX | $94.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1138.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -13.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -7.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -22.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeOnc Technologies's revenue per employee in the last FY averaged $28K, while opex per employee averaged $2.4M for the same period.
NeOnc Technologies's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeOnc Technologies's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NeOnc Technologies and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10958% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $28K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3669% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8656% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeOnc Technologies acquired XXX companies to date.
Last acquisition by NeOnc Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . NeOnc Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NeOnc Technologies founded? | NeOnc Technologies was founded in 2005. |
| Where is NeOnc Technologies headquartered? | NeOnc Technologies is headquartered in United States of America. |
| How many employees does NeOnc Technologies have? | As of today, NeOnc Technologies has 3 employees. |
| Who is the CEO of NeOnc Technologies? | NeOnc Technologies's CEO is Dr. Thomas Chen, M.D.,PhD. |
| Is NeOnc Technologies publicy listed? | Yes, NeOnc Technologies is a public company listed on NAS. |
| What is the stock symbol of NeOnc Technologies? | NeOnc Technologies trades under NTHI ticker. |
| When did NeOnc Technologies go public? | NeOnc Technologies went public in 2025. |
| Who are competitors of NeOnc Technologies? | Similar companies to NeOnc Technologies include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of NeOnc Technologies? | NeOnc Technologies's current market cap is $94.6M |
| Is NeOnc Technologies profitable? | Yes, NeOnc Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
